Dear All, Last fall, the team at ATMF (Access to Medicine Foundation) released the 3rd update to the AMR Benchmark series and Damiano de Felice was a guest author for a newsletter about the findings. That report offered a wealth of granular data, in-depth analyses and revealing graphs about what pharmaceutical companies in the global antibiotic and
Dear All, A Notice of Special Interest (a “NOSI” in NIH jargon; here’s the link: NOT-ES-22-006) from the NIH could be something of interest for AMR R&D. This NOSI has > 10 of the Institutes behind it and as summarized on the website “this NOSI encourages applications that address the impact of climate change on health
Dear All (Wonkish alert! Get some coffee and settle in!), Almost in parallel, EMA and FDA have released updates to key antibacterial guidance documents! Here are the links you’ll need and I’ve highlighted the key documents. To go deeper, you’ll need to pick through everything and I provide a tour further below in this newsletter: EMA’s
Dear All, In a report entitled Understanding the Antibiotic Manufacturing Ecosystem: A view of global supply chains, pressure points, and implications for antimicrobial resistance response, the Boston Consulting Group and Wellcome Trust have examined at length the questions of (i) how the #FireExtinguishersOfMedicine are made and (ii) how they can be made with the least impact
Dear All, The US Office of the Assistant Secretary for Preparedness & Response (ASPR) is looking for comments on the 2023-2026 National Health Security Strategy (NHSS). They would like input from stakeholders in public health, healthcare, emergency management, national security, non-governmental organizations, academia, and private industry. Their specific questions to consider are: What are the most critical national health
Dear All, As you may remember, last fall I wrote a newsletter about ATMF’s 3rd update to the AMR Benchmark series. You are encouraged to read the report but in brief, the key messages are (i) the pipeline is small with most innovation coming from small biotech, (ii) stewardship and access planning are increasingly seen (but access itself
Dear All, NIAID and RTI International have recently announced the initiation of CC4CARB Chemistry Center for Combating Antibiotic Resistance). In brief, CC4CARB synthesizes compound libraries (free of charge!) based on scaffolds that you propose The focus is on creating novel chemical matter that might have antibacterial activity (there appears to be a focus on Gram-negatives, but there
Dear All, I learned today from our colleagues at WHO that Alphafold has recently added the proteome of nearly all the WHO priority pathogens to their library of highly accurate prediction of protein structures. Alphafold was new to me and is amazing! Per our colleagues at WHO: AlphaFold is an AI system developed by DeepMind that
Dear All, Whew … still catching up after all the activities of World Antimicrobial Awareness Week (WAAW)! More to follow on some of that great content, but for today we have the news that FDA has posted 4 RFPs! All have due dates of 21 Jan 2022: Optimizing dosing strategies for obese patients and in continuous
Dear All, WHO are looking for multidisciplinary university groups or other scientific institutions to support the development of a One Health Priority Research Agenda on AMR! Per the RFP on the UN website (https://www.ungm.org/Public/Notice/146908), the terms of reference include scientific and methodological support for the following activities: Review of the grey literature and policy analysis of